Clinical trials: Covid19 Vaccine
Healthy Volunteers
Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers
The clinical trial is a phase1/2a, open-label, dose-escalating, multicentre trial evaluating the safety and immunogenicity of the CD40.Pan.CoV vaccine, adjuvanted or not, as a booster injection in adult participants in France.
- Trial name
- PANCOV (NCT07113106)
- Testing
- CD40.Pan.CoV Low dose(0.25mg), CD40.Pan.CoV Low dose (0,25mg) adjuvanted with Hiltonol®, CD40.Pan.CoV High dose (1mg)
- Where
- 7 sites in France
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Severe Acute Respiratory Syndrome (SARS-CoV-2 Virus)
Bio-Manguinhos/Fiocruz COVID-19 (mRNA) Vaccine Booster
This is a descriptive, open-label, multicenter, non-randomized, uncontrolled phase I clinical study to evaluate the safety, reactogenicity, and immunogenicity of the COVID-19 Vaccine (mRNA) - Bio-Manguinhos/Fiocruz at doses of 25…
- Trial name
- NCT07640308
- Testing
- Grupo 1 - dose 25 μg, Group 2 - 50 μg dose, Group 3 - 100 μg
- Volunteers
- 90 people
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Coronavirus, Covid19
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of investigational SARS-CoV-2 mRNA vaccine (CVnCoV) at different dose levels and to evaluate the humoral immune response after 1…
- Conditions
- Coronavirus, Covid19, SARS-CoV-2, Severe Acute Respiratory Syndrome
- Trial name
- NCT04515147
- Testing
- CVnCoV 6 μg, CVnCoV 12 μg, Hepatitis A vaccine
- Where
- 2 sites in Panama, Peru
- Volunteers
- 668 people, healthy volunteers welcome
- Sponsor
- CureVac
COVID-19, SARS-CoV-2 Infection
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.
The objective of this study is to evaluate the safety, tolerability, and immunogenicity of SCTV01C in healthy population aged ≥18 years previously vaccinated with inactivated COVID-19 vaccine.
- Trial name
- NCT05043285
- Testing
- SCTV01C
- Where
- United Arab Emirates
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19 Vaccines
Variables Influencing Anti-COVID-19 Vaccinations Around the World: an Analysis Conducted on Aggregated Data Sourced From Institutional Databases to Understand Whether and How Different Variables Could Affect the Vaccine Coverage (WORLDCOV: Worldwide Determinants of COVID-19 Vaccination)
Vaccination coverage against COVID-19 differs widely between countries: in order to address this public health issue, this observational study seeks to understand whether there are any determinants/predictors.
- Trial name
- WORLDCOV (NCT05471635)
- Testing
- COVID-19 Vaccine
- Where
- Italy
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Alberto Peano
SARS-CoV-2, COVID-19
A Study of the Effectiveness of Moderna COVID-19 Vaccine
This is an observational cohort study to evaluate real-world vaccine effectiveness and durability of Moderna COVID-19 vaccine among a diverse population at Kaiser Permanente Southern California (KPSC).
- Trial name
- NCT05933304
- Where
- United States
- Volunteers
- 927,004 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Microbiome, Vaccine
Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines
Vaccination is the best way to mitigate the coronavirus disease 2019 (COVID-19) pandemic, but the vaccine immunogenicity may be quite variable from person to person.
- Conditions
- Microbiome, Vaccine, Covid-19, SARS-CoV-2
- Trial name
- NCT05150834
- Testing
- This is observational study
- Where
- South Korea
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
COVID-19, Chronic Bronchitis
Immunogenicity and Safety of a Third Dose and Immune Persistence of BBIBP-Corv Vaccine in Elderly People With Chronic Bronchitis and COPD
Evaluation of immunogenicity, safety and persistence of the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease received the third dose of inactivated COVID-19 vaccine .
- Conditions
- COVID-19, Chronic Bronchitis, COPD
- Trial name
- NCT05104216
- Testing
- Inactivated COVID-19 vaccine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- China National Biotec Group Company Limited
Covid19
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
This is a Phase 1 clinical trial to assess the safety and immunogenicity of AdCLD-CoV19-1 in healthy adults.
- Trial name
- NCT05047692
- Testing
- AdCLD-CoV19-1
- Where
- 3 sites in South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cellid Co., Ltd.
Coronavirus Disease 2019
Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine
Popular topic：Clinical study of recombinant Novel Coronavirus vaccine (CHO cell) combined with influenza vaccine. Research purpose:Main purpose:To evaluate the immunogenicity of recombinant Novel Coronavirus vaccine (CHO cells)…
- Trial name
- NCT05107375
- Testing
- Tetravalent influenza virus lysis vaccine, Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 299 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Healthy Adults
An Experimental Medicine Multicenter Trial to Evaluate the Safety and Immunogenicity of Experimental Versus Authorized SARS-CoV-2 Vaccine Candidates as a Booster Dose in Healthy Participants Previously Vaccinated With Authorized mRNA SARS-CoV-2 Vaccines.
The SOLVE-01 trial is a study evaluating four SARS-CoV-2 vaccines as booster injections: two experimental vaccines (CD40.RBDv and CD40.Pan.CoV, both combined with the Hiltonol® adjuvant) and two authorised vaccines (Comirnaty®…
- Trial name
- SOLVE-01 (NCT07605520)
- Testing
- CD40.RBDv vaccine adjuvanted with Hiltonol®, CD40.Pan.CoV vaccine adjuvanted with Hiltonol®, Comirnaty® vaccine
- Where
- 3 sites in France, Switzerland
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Healthy
Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults
This Phase I/II trial in France evaluates safety and immunogenicity of a booster dose of an intranasal COVID-19 vaccine (LVT-001) versus a booster dose of a COVID-19 mRNA vaccine (Pfizer-BioNTech) in healthy adult volunteers.
- Trial name
- MUCOBOOST (NCT06821126)
- Testing
- LVT-001, Cormirnaty
- Where
- 5 sites in France
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Vaccine Hesitancy, COVID-19
The Impact of a Web-based Psychoeducation Programme with a Motivational AI Chatbot on Covid-19 Vaccine Hesitancy
Vaccine hesitancy is defined as 'delay in acceptance or refusal of vaccines, despite the availability of vaccine service' and was named one of the top ten global health threats by the World Health Organization in 2019.
- Trial name
- NCT05531058
- Testing
- AI-driven Vaccine Communicator, Self-learning of COVID-19 vaccine knowledge
- Where
- Hong Kong
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- The Hong Kong Polytechnic University
Covid19
Equitable Access to COVID-19 Vaccines
This study will deploy a multimodal pragmatic intervention to improve vaccine uptake in priority populations and address vaccine hesitancy to improve access by using a proactive organized population-based outreach leveraging…
- Trial name
- NCT04952376
- Testing
- SMS delivery of information, Personalized text message delivery of information, Interactive or 2-way SMS delivery of information
- Where
- United States
- Volunteers
- 1,722 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
COVID-19
Intradermal COVID-19 Vaccination in the Immunocompromised
COVID-19 is an infectious disease caused by SARS-CoV-2 virus, causing millions of deaths around the globe since the beginning of the pandemic.
- Trial name
- NCT05736913
- Testing
- ID BNT162b2 vaccine, IM BNT162b2 vaccine
- Where
- Hong Kong
- Volunteers
- 130 people
- Sponsor
- The University of Hong Kong
SARS-CoV-2, COVID-19
Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years
The purpose of this post-marketing study is to assess the safety of Comirnaty monovalent XBB.1.5. for booster vaccination children ages 6 months though 4 years under actual use medical practice.
- Trial name
- NCT06130410
- Testing
- COMIRNATY intramuscular injection
- Where
- Japan
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
Coronavirus Infections, Healthy
Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine
NDV-HXP-S is an inactivated COVID-19 vectored-vaccine virus using the Newcastle Disease Virus as basis and expressing Spike (S) protein from SARS-CoV-2 stabilized in pre-fusion form with Hexapro technology.
- Trial name
- Butanvac (NCT05354024)
- Testing
- NDV-HXP-S 10μg, BNT162b2 30μg
- Where
- 6 sites in Brazil
- Volunteers
- 4,400 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Covid19
Potential Acceptance of COVID-19 Vaccines in Healthcare Workers in Egypt
The COVID-19 pandemic is expected to remain as a public health threat and economic burden all over the world. The available proposed vaccines are still lacking large randomized controlled trials testing its efficacy and safety.
- Trial name
- NCT04694651
- Where
- 2 sites in Egypt
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Assiut University
COVID-19
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine (ABO1020) in Healthy Subjects Aged 18 Years and Older Who Have…
- Trial name
- NCT05636319
- Testing
- ABO1020
- Where
- 25 sites in Indonesia, Pakistan and 2 more
- Volunteers
- 14,168 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
COVID-19
Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19
The purpose of this double-blind, randomized, controlled study is to assess safety, reactogenicity, and immunogenicity of ZR-202-CoV, administered as 2 injections (i.m) at 28 days apart in adult subjects 60 years of age and above.
- Trial name
- NCT05313022
- Testing
- ZR-202-CoV
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.